News

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

Expert John Sergent shares insight on his best practices treating patients with autoimmune diseases.

The advent of biologics has transformed care for patients with inflammatory bowel disease.

Severe and level 2 hypoglycemia has continued to occur in individuals with type 1 diabetes and high hypoglycemia risks despite technological advancements.

In honor of Autoimmune Disease Awareness Month, expert Dr. Joe Ahearn and advocate Michael Linn discuss relapsing polychondritis.

There is a need to study more combination therapies for the treatment of inflammatory bowel disease.

Interstitial lung disease expert explains the importance of educating patients with autoimmune disease.

Dr. Elena B. Hawryluk details her pre-AAD session, the variety of conversations being held at the meeting, and how these conversations can inform dermatological research outside of the pediatric field.

Authors call for further investigation of pathophysiological pathways between rheumatoid arthritis and primary open-angle glaucoma.

RBX2660 is a live microbiome therapeutics that could build on the success of fecal microbiota transplantation for treating patients with recurrent C difficile infections.

Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.

Data from Australia show a T-cell antigen-inducing vaccine was unable to provide greater prevention of flu incidence than a placebo.

Large variations were observed in the transition between monotherapy and dual combination therapy for hypertension across countries and demographic group.

Dr. Rees spoke of how addressing issues of representation could improve upon disparities in health care not only in the pediatric space but across all fields.

Limited physical function, fatigue, mental health issues (resulting from chronic disease), and medication issues can further affect the ability of children with rheumatic disease from performing well in school.

IL-17 inhibitors were also associated with higher persistence than IL-12 and IL-23 inhibitors for psoriatic arthritis, though no difference was observed for psoriasis.

There was an independent association between in-hospital mortality and a neutrophil ratio greater than 75%, serum creatinine of at least 1.5 mg/L, and CDI caused by isolates harboring the tcdC gene.

Recent studies suggest that a gap in cardiovascular risk remains between patients with rheumatoid arthritis and the general population.

Strategies to improve enrollment of underrepresented populations were centered on study design and site selection, community engagement, and changing the research paradigm.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

A retrospective study analyzed patients with systemic sclerosis to determine prevalence, severity, and mortality within this patient population.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

Case-control analyses suggest older patients may cognitively age by about 8 years within 6 months of being discharged for severe COVID-19.

A favorable lifestyle is associated with a lower risk of coronary artery disease in carriers and noncarriers of FH variants.

Investigators found 31% of patients treated with aldafermin 0.3 mg had an improvement in liver fibrosis of at least 1 stage with no worsening of NASH.

The Director of Policy and Advocacy for the US Pain Foundation addresses the important changes made to the updated draft of the CDC Clinical Practical Guideline for Prescribing Opioids 2022.

Cross-sectional analysis of national survey data suggest students with multiple marginalized identities are more prone to treatment that could lead to burnout.

Patients with Fabry disease who received treatment with PRX-102 every 4 weeks displayed a stable condition at the end of the trial.

Dr. Bajona highlights the patient risks of HCM, new advances in treatment options, and the importance of screening efforts.

Children exposed and not exposed to neonatal hypoglycemia did not have significant differences in rates of low educational performance at 9 to 10 years old.